Sanjiv S. Agarwala, MD, chairman of medical oncology at St. Luke’s University Health Network, discusses the combination of immunotherapy and a histone deacetylase inhibitor in patients with melanoma, as well as other types of cancer.
Sanjiv S. Agarwala, MD
Advertisement
Articles by Sanjiv S. Agarwala, MD
Advertisement
Latest Updated Articles
Combining HDAC Inhibitors With Immunotherapy in MelanomaPublished: September 7th 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
